Skip to main content

Table 3 Immunogenicity results at 43 days post-each dose (according-to-protocol cohort for immunogenicity)

From: Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

 

Group Var-HSA

Group Var+HSA

N

SRR (95% CI), %

GMC (95% CI), mIU/mL

N

SRR (95% CI), %

GMC (95% CI), mIU/mL

Post-dose 1

185

94.1 (89.6–97.0)

139.9 (126.7–154.5)

168

98.8 (95.8–99.9)

146.0 (132.5–160.7)

Post-dose 2

180

100 (98.0–100)

931.8 (841.1–1032.3)

173

100 (97.9–100)

1102.4 (996.1–1220.2)

  1. Group Var-HSA participants receiving varicella vaccine produced without HSA (human albumin serum), Group Var+HSA participants receiving varicella vaccine containing HSA, N number of participants with available results, SRR seroresponse rate, CI confidence interval, GMC geometric mean concentration, IU international units
  2. Note: Seroresponse was defined as post-vaccination anti-varicella-zoster virus antibody concentrations ≥50 mIU/mL